Form 4: Inogen CEO Kevin Smith Reports Stock Transactions Following Vesting of Restricted Stock Units

Inogen CEO Kevin Smith acquired 28,333 shares of common stock through the vesting of restricted stock units and subsequently sold 13,779 shares to cover tax obligations.

Summary

• Inogen CEO Kevin Smith acquired 28,333 shares of common stock on December 1, 2024, through the vesting of restricted stock units.
• Following the vesting, 13,779 shares were sold at a price of $9.71 per share to cover tax liabilities.
• The transactions resulted in a net increase of 14,554 shares of common stock held by Mr. Smith.
• Mr. Smith also holds 56,667 restricted stock units after the transaction.

Sentiment

Score: 5

Explanation: The document is a routine filing of stock transactions by an executive, which is neither positive nor negative in itself. It reflects standard compensation practices.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Executive stock transactions are a common practice in publicly traded companies, particularly in the technology and medical device sectors.
• Companies like ResMed (RMD) and Philips (PHG) also have similar reporting requirements for their executives' stock transactions.
• The vesting schedule of 1/3rd per year is a fairly standard practice for restricted stock units.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.
• The sale of shares to cover tax obligations is a standard practice and does not indicate any change in the company's outlook.

Key Dates

Keywords

Inogen, stock, restricted stock units, vesting, CEO, insider trading, Form 4, equity